BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BCLI
Neutral
medium confidence
Mentioned
$BCLI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BCLINeutralMed
01

Why it matters

Traders can use the updated quarterly cash, operating expense run-rate, and net loss to reassess funding needs and the probability of progressing to Phase 3b initiation, while the executive-chair appointment and FDA-related commentary may influence perceived regulatory execution quality.

02

Market read

This is a primary quarterly disclosure plus program-readiness update, useful for reassessing liquidity and near-term trial execution risk for an OTC biotech.

03

What to watch

Cash is still very low (about $0.35M cash and restricted cash at Sept. 30, 2026) and liabilities are sizable versus assets, increasing sensitivity to any future dilutive financing or delays in trial initiation.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Nov 16, 2026

Background

BrainStorm Cell Therapeutics (OTCQB: BCLI) furnished an SEC Form 8-K with Q3 2026 results and a corporate update focused on NurOwn in ALS, including Phase 3b ENDURANCE preparations under an FDA Special Protocol Assessment.

Company-level read

Ticker impact

$BCLINeutralMedium confidence
Context

BrainStorm reports Q3 2026 financials and says it is preparing to initiate the Phase 3b ENDURANCE study of NurOwn under an FDA-agreed SPA.

Expected impact

Likely modest sentiment support from Phase 3b readiness updates, offset by continued small cash balance and ongoing net losses.

Evidence & confidence

This is a primary 8-K with new quarter results and specific program readiness statements, but it does not include trial outcomes, financing terms, or a clear catalyst date that would drive a large repricing.

Market effects

Adds incremental signal on FDA rare-disease regulatory posture and how stem-cell neurodegeneration programs are progressing toward late-stage studies.

No clear regional spillover beyond OTC biotech sentiment.

Limited; the update is company-specific with only general reference to FDA’s rare disease framework initiative.

Counterpoint

The Phase 3b readiness language may not translate into near-term enrollment or cash runway, so the market may focus more on burn rate and liquidity risk than on regulatory progress.

Key entities

  • BrainStorm Cell Therapeutics Inc.

    OTCQB-listed adult stem cell therapeutics developer reporting Q3 2026 results and NurOwn Phase 3b ENDURANCE readiness updates.

  • NurOwn

    Autologous MSC-NTF cell therapy platform for ALS; company highlights Phase 3b ENDURANCE preparations under an FDA-agreed SPA.

  • FDA Special Protocol Assessment (SPA)

    FDA-agreed protocol framework referenced as supporting the planned Phase 3b ENDURANCE study.

  • Professor Peter J. Pitts

    Appointed Executive Chairman and Chief Strategic Regulatory and Policy Officer to lead regulatory, operational, partnership, and capital-markets initiatives.

Related articles

$BCLIMed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

$SUNEMed

SUNATION ENERGY ANNOUNCES THIRD QUARTER 2026 RESULTS; REPORTS SEQUENTIAL REVENUE AND GROSS MARGIN IMPROVEMENT AND PROVIDES SUNIVA MERGER UPDATE

SUNation Energy, Inc. (SUNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SUNATION ENERGY ANNOUNCES THIRD QUARTER 2026 RESULTS; REPORTS SEQUENTIAL REVENUE AND GROSS MARGIN IMPROVEMENT AND PROVIDES SUNIVA MERGER UPDATE Third-quarter revenue of $11.2 million increased from $8.2 million in the second quarter; year-over-year results continued

$TRUGMed

TruGolf Reports Top Third Quarter Results

TruGolf Holdings, Inc. (TRUG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TruGolf Reports Top Third Quarter Results Third Quarter Revenue Up 29.4% Year-over-Year to $5.3 Million Salt Lake City, Utah, November 16, 2026 - TruGolf Holdings, Inc. (NASDAQ: TRUG), the owner of TruGolf, a leading provider of golf simulator software and hardware,